News | March 17, 2026
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
The facility is expected to become operational by FY2028-29
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Subscribe To Our Newsletter & Stay Updated
